Notice: This company has been marked as potentially delisted and may not be actively trading. Pieris Pharmaceuticals (PIRS) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock Pieris Pharmaceuticals (NASDAQ:PIRS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.39%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$92,311.00Number OfInsiders Selling(Last 12 Months)0 Get PIRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Pieris Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PIRS Insider Buying and Selling by Quarter Remove Ads Pieris Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/12/2024Adar1 Capital Management, LlcMajor ShareholderBuy3,000$15.88$47,640.00 8/9/2024Adar1 Capital Management, LlcMajor ShareholderBuy3,000$14.89$44,670.00 8/7/2024James A GeraghtyDirectorBuy1$1.00$1.00 (Data available from 1/1/2013 forward) PIRS Insider Trading Activity - Frequently Asked Questions Who is on Pieris Pharmaceuticals's Insider Roster? The list of insiders at Pieris Pharmaceuticals includes Adar1 Capital Management, Llc, Christopher P Kiritsy, James A Geraghty, and Tim Demuth. Learn more on insiders at PIRS. What percentage of Pieris Pharmaceuticals stock is owned by insiders? 6.39% of Pieris Pharmaceuticals stock is owned by insiders. Learn more on PIRS's insider holdings. Which Pieris Pharmaceuticals insiders have been buying company stock? The following insiders have purchased PIRS shares in the last 24 months: Adar1 Capital Management, Llc ($92,310.00), Christopher P Kiritsy ($8,500.00), and James A Geraghty ($1.00). How much insider buying is happening at Pieris Pharmaceuticals? Insiders have purchased a total of 6,126 PIRS shares in the last 24 months for a total of $100,811.00 bought. Pieris Pharmaceuticals Key ExecutivesMr. Stephen S. Yoder J.D. (Age 48)CEO, President & Director Compensation: $744.13kMr. Thomas Bures (Age 49)Senior VP, CFO & Treasurer Compensation: $487.5kDr. Shane Olwill Ph.D. (Age 48)Senior VP & Chief Development Officer Compensation: $463.91kMaria KelmanExecutive Director of Investor RelationsMr. Prompong Chaikul (Age 37)Chief Supply Chain Officer Dr. Florian Witte Ph.D.VP and Head of Alliance Management & Early Project Leadership More Insider Trading Tools from MarketBeat Related Companies MediciNova Insider Selling Skye Bioscience Insider Selling ESSA Pharma Insider Selling Acrivon Therapeutics Insider Selling Clearside Biomedical Insider Selling IGM Biosciences Insider Selling Cabaletta Bio Insider Selling Acumen Pharmaceuticals Insider Selling Corbus Pharmaceuticals Insider Selling Assertio Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Casey’s General Stores Insider Buys Shares of This Must-Own StockNVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish This page (NASDAQ:PIRS) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
